Larimar Therapeutics Inc (OQ:LRMR)

Sep 20, 2022 09:31 am ET
Thinking about buying stock in Cognex, Norwegian Cruise Line, The Metals Company, Larimar Therapeutics, or Peloton Interactive?
NEW YORK, Sept. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGNX, NCLH, TMC, LRMR, and PTON.
Sep 19, 2022 08:33 am ET
Thinking about buying stock in Purple Innovation, Knowbe4, Allakos, Larimar Therapeutics, or Alzamend Neuro?
NEW YORK, Sept. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRPL, KNBE, ALLK, LRMR, and ALZN.
Sep 16, 2022 01:00 pm ET
Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares
Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten offering...
Sep 14, 2022 07:04 am ET
Larimar Therapeutics Announces $70 Million Underwritten Offering
Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of an underwritten offering of 22,225,000 shares...
Sep 14, 2022 07:01 am ET
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the initiation of...
Aug 11, 2022 04:05 pm ET
Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received meeting minutes from the U.S. Food and Drug...
Jul 28, 2022 04:05 pm ET
Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that preclinical studies evaluating CTI-1601’s effects on gene expression and...
Jun 28, 2022 08:00 am ET
Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially...
Jun 02, 2022 08:00 am ET
Larimar Therapeutics Announces Upcoming Scientific Conference Presentations
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced upcoming presentations at the United Mitochondrial Disease Foundation...
May 19, 2022 08:00 am ET
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a...
May 12, 2022 07:00 am ET
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2022 operating and financial results. “The FDA recently...
Mar 25, 2022 07:00 am ET
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its full year 2021 operating and financial results. “The past year was...
Mar 09, 2022 05:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK, March 9, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Mar 01, 2022 01:20 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
NEW YORK, March 1, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Feb 22, 2022 08:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Feb 17, 2022 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Larimar Therapeutics, Inc. (LRMR) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Investors who purchased Larimar shares are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bga
Feb 16, 2022 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Larimar Therapeutics, Inc. (LRMR) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Investors who purchased Larimar shares are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bga
Feb 15, 2022 07:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Feb 14, 2022 04:01 pm ET
Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA)...
Nov 22, 2021 07:00 am ET
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at...
Nov 15, 2021 07:00 am ET
Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the...
Nov 12, 2021 07:00 am ET
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date September 30, 2021 operating and financial...
Sep 16, 2021 08:00 am ET
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB...
Sep 02, 2021 04:01 pm ET
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar...
Aug 19, 2021 07:00 am ET
Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of...
Aug 12, 2021 07:00 am ET
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
Subcutaneous injections of CTI-1601 at doses of 50 mg or 100 mg resulted in frataxin levels in buccal cells of FA patients that were at or in excess of those that would be expected in phenotypically normal heterozygous carriers - Phase 1...
Jul 08, 2021 04:01 pm ET
Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar...
Jul 06, 2021 10:30 am ET
Thinking about buying stock in Exela Technologies, Larimar Therapeutics, Marin Software, Provention Bio, or BioLineRx?
NEW YORK, July 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, LRMR, MRIN, PRVB, and BLRX.
Jun 11, 2021 07:00 am ET
Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar...
Jun 02, 2021 10:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
May 25, 2021 05:41 pm ET
Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that the United States Food and Drug...
May 21, 2021 09:18 am ET
Larimar Therapeutics Announces $95 Million Private Placement Financing
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that it has executed a securities purchase...
May 20, 2021 04:31 pm ET
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced that the European Medicines Agency (EMA)...
May 11, 2021 07:00 am ET
Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for Friedreich’s ataxia (FA) and other complex rare diseases, today announced topline data from its Phase 1 multiple...
May 10, 2021 04:05 pm ET
Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2021 operating and financial results. “Our Phase 1 program...
Mar 04, 2021 07:00 am ET
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2020 operating and financial results. “2020...
Feb 18, 2021 04:01 pm ET
Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar...
Dec 15, 2020 08:00 am ET
Larimar Therapeutics Added to NASDAQ Biotechnology Index
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index...
Dec 08, 2020 07:30 am ET
Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of dosing from the Company’s Phase 1 single ascending dose...
Nov 13, 2020 08:00 am ET
Larimar Therapeutics to Participate in Upcoming Investor Conferences
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will...
Nov 10, 2020 08:00 am ET
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2020 operating and financial results. “I am very pleased with the...
Oct 13, 2020 08:00 am ET
Larimar Therapeutics Announces Formation of Scientific Advisory Board
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the formation of its Scientific Advisory Board (SAB). Larimar’s SAB is comprised of...
Sep 21, 2020 09:58 am ET
Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will virtually present...
Aug 11, 2020 07:00 am ET
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2020 operating and financial results. “The second quarter was a...
Aug 04, 2020 08:00 am ET
Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will present at the 2020...
Jul 28, 2020 08:00 am ET
Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP)...
Jul 20, 2020 04:15 pm ET
Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that patients have been dosed in the third cohort of a Phase 1 clinical trial to evaluate...
May 29, 2020 04:05 pm ET
Larimar Therapeutics to Present at Jefferies Virtual Healthcare Conference
Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer, will present at the...
May 29, 2020 08:00 am ET
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of its reverse merger with Zafgen, Inc. (Nasdaq:ZFGN). The combined, publicly traded...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.